Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Active, not recruiting · NCT06612203 · Registry updated 2025-12-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer | Advanced Breast Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2025-12-05 | NCT06612203 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Debiopharm International SA | 10 |
| Gilead Sciences | 180 |
| MedSIR | 19 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Barts Health NHS Trust | London | United Kingdom | 30 |
| Beatson West of Scotland Cancer Center | Glasgow | United Kingdom | 2 |
| Hospital Arnau de Vilanova de Valencia | Valencia | Spain | 7 |
| Hospital Beata María Ana | Madrid | Spain | 5 |
| Hospital Universitari Dexeus | Barcelona | Spain | 7 |
| Hospital Universitario Clínico San Cecilio de Granada | Granada | Spain | 5 |
| Hospital Universitario Virgen de la Victoria | Málaga | Spain | 24 |